Compare JJSF & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | NBTX |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | France |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1995 | 2018 |
| Metric | JJSF | NBTX |
|---|---|---|
| Price | $85.40 | $31.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $110.50 | $54.14 |
| AVG Volume (30 Days) | ★ 188.9K | 124.5K |
| Earning Date | 11-18-2026 | 09-24-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.98 | $50.69 |
| P/E Ratio | $42.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $17.43 |
| 52 Week High | $98.63 | $57.14 |
| Indicator | JJSF | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.67 | 54.98 |
| Support Level | $77.64 | $30.15 |
| Resistance Level | $88.12 | $35.38 |
| Average True Range (ATR) | 2.13 | 1.76 |
| MACD | 0.58 | 1.50 |
| Stochastic Oscillator | 90.43 | 74.72 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.